BYM338 in Chronic Obstructive Pulmonary Disease (COPD) Patients With Cachexia
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
This study will assess the pharmacodynamics, pharmacokinetics, safety and tolerability of
BYM338 in patients with COPD and cachexia. The primary outcome will be a change in thigh
muscle volume compared to placebo. The study will last for approximately 24 weeks.